Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 – Investor's Business Daily

This article was originally published on this site

On Thursday, Heron Therapeutics (HRTX) earned an upgrade to its Relative Strength (RS) Rating, from 86 to 92.

X IBD’s proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price performance over the trailing 52 weeks stacks up against all the other stocks in our database.

Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their biggest runs.


Looking For The Best Stocks To Buy And Watch? Start Here


Heron Therapeutics has climbed more than 5% past a 17.55 entry in a first-stage cup with handle, meaning it’s now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.

In terms of top and bottom line numbers, Heron Therapeutics has posted rising EPS growth in each of the last four reports. Sales gains have been less impressive, coming in at 0% in the latest report.

Heron Therapeutics earns the No. 47 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND) and Vertex Pharmaceuticals (VRTX) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock